By Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
Patients last year petitioned the FDA to consider the treatment, called NurOwn, in a public hearing. The agency said the company submitted"scientifically incomplete" and"grossly deficient" data.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsThe biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Consulte Mais informação »
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
Consulte Mais informação »
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Consulte Mais informação »
San Diego biotech will pay $200K after allegations of misleading claimsBiora Therapeutics made misleading claims regarding the costs of genetic testing services
Consulte Mais informação »
Average teen gets more than 230 notifications on their cell phone each day, study findsA new study is shining a light on the amount of time teenagers are spending on their cell phones and social media every day.
Consulte Mais informação »